| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.0000168410.44722.86 |
| P698 | PubMed publication ID | 15860745 |
| P2093 | author name string | Jong-Oh Kim | |
| Michael Weis | |||
| Sieglinde Kofler | |||
| Michael Nabauer | |||
| Heiko Methe | |||
| P2860 | cites work | Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 1439-1445 | |
| P577 | publication date | 2005-04-28 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes | |
| P478 | volume | 25 |
| Q37122453 | A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity |
| Q36392153 | Atorvastatin Reduces the Survival of Candida albicans-Infected BALB/c Mice |
| Q39252677 | Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells |
| Q92578163 | Atorvastatin increases the production of proinflammatory cytokines and decreases the survival of Escherichia coli-infected mice |
| Q39426447 | Atorvastatin inhibits functional expression of proatherogenic TLR2 in arterial endothelial cells. |
| Q42379555 | Atorvastatin regulates apoptosis in chronically ischemic myocardium |
| Q90019127 | CD34+ circulating cells display signs of immune activation in patients with acute coronary syndrome |
| Q84913825 | Can statins reduce the inflammatory response associated with preterm birth in an animal model? |
| Q41969861 | Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo |
| Q89908699 | Clostridium difficile Infection: An Epidemiology Update |
| Q37169130 | Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases |
| Q37979794 | Dysregulated inflammation as a risk factor for pneumonia in the elderly |
| Q35456704 | Early statin use is associated with increased risk of infection after stroke. |
| Q36293678 | Effects of Toll-Like Receptor Signals in T-Cell Neoplasms |
| Q34633305 | Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs |
| Q44743116 | Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction |
| Q42772478 | Effects of simvastatin on the function of dendritic cells in patients with rheumatic arthritis |
| Q59341933 | El monocito/macrófago como diana terapéutica en la aterosclerosis |
| Q39732662 | Glucose-based peritoneal dialysis fluids downregulate toll-like receptors and trigger hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells |
| Q84232214 | HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients |
| Q46574967 | HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation |
| Q34763977 | High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial |
| Q27024964 | Hyperlipidemia, tissue factor, coagulation, and simvastatin |
| Q34269660 | Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia |
| Q40068676 | Increased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin |
| Q38557048 | Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics |
| Q37364297 | Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q54309368 | Loss of toll-like receptor 3 function improves glucose tolerance and reduces liver steatosis in obese mice |
| Q26771553 | Macrophages and Alcohol-Related Liver Inflammation |
| Q38473474 | Mechanisms and management of doxorubicin cardiotoxicity |
| Q36443075 | Mevalonate Biosynthesis Intermediates Are Key Regulators of Innate Immunity in Bovine Endometritis |
| Q42491380 | Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors |
| Q40679113 | Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin |
| Q39979826 | Myeloid cell differentiation in response to calcitriol for expression CD11b and CD14 is regulated by myeloid zinc finger-1 protein downstream of phosphatidylinositol 3-kinase |
| Q50668087 | Overexpression of Toll-Like Receptors 2, 3, 4, and 8 Is Correlated to the Vascular Atherosclerotic Process in the Hyperlipidemic Rabbit Model: The Effect of Statin Treatment |
| Q35655728 | Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. |
| Q30341525 | Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis. |
| Q35169285 | Prior statin use and 90-day mortality in Gram-negative and Gram-positive bloodstream infection: a prospective observational study |
| Q52615374 | Probucol Attenuates Inflammation and Increases Stability of Vulnerable Atherosclerotic Plaques in Rabbits |
| Q44463455 | Reduction in mortality associated with statin therapy in patients with severe sepsis |
| Q47658886 | Role of Toll-like receptors in infection and immunity: clinical implications |
| Q40835741 | Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense. |
| Q35102167 | Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy |
| Q37528422 | Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy |
| Q35074866 | Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels |
| Q38357522 | Simvastatin inhibits TLR8 signaling in primary human monocytes and spontaneous TNF production from rheumatoid synovial membrane cultures |
| Q37691945 | Simvastatin inhibits lipopolysaccharide-induced osteoclastogenesis and reduces alveolar bone loss in experimental periodontal disease |
| Q36882289 | Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation |
| Q37456616 | Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. |
| Q40738275 | Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders. |
| Q48867291 | Statins amplify TLR-induced responses in microglia via inhibition of cholesterol biosynthesis. |
| Q36369699 | Statins in the critically ill |
| Q46158768 | Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes |
| Q40595089 | TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients |
| Q54717063 | TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients. |
| Q38553529 | Targeting inflammation in metabolic syndrome. |
| Q38044110 | The Biological Role of Inflammation in Atherosclerosis |
| Q83827966 | The Effect of Herb-Partition Moxibustion on Toll-like Receptor 4 in Rabbit Aorta during Atherosclerosis |
| Q42152131 | The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease |
| Q90421576 | The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line |
| Q83401137 | The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications |
| Q33529187 | The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. |
| Q37696961 | The role of Toll-like receptors in renal diseases |
| Q33610240 | Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair |
| Q36382348 | Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms |
| Q36453194 | Toll-like Receptors in the Vascular System: Sensing the Dangers Within |
| Q37731959 | Toll-like receptor 4 modulation as a strategy to treat sepsis |
| Q37954396 | Toll-like receptors and diabetes: a therapeutic perspective |
| Q37850809 | Toll-like receptors as potential therapeutic targets in cardiac dysfunction |
| Q37954284 | Toxins–Useful Biochemical Tools for Leukocyte Research |
| Q35674383 | Understanding the expression of Toll-like receptors in Asian Indians predisposed to coronary artery disease |
| Q37470209 | Update on statin-mediated anti-inflammatory activities in atherosclerosis |
| Q37975897 | Vascular effects of glycoprotein130 ligands--part II: biomarkers and therapeutic targets |
Search more.